Leveraging Experience From Active TB Drug-Safety Monitoring and Management for Monitoring Active Antiretroviral Toxicity

• Published in: Global health science and practice Vol. 10; no. 2; p. e2100595
• Main Authors: Stevens, Lisa, Perry, Kelly E, Moide, Iakuna, Kaemala, Francil, Nankinga, Justine, Innes, Anh L, Mogaba, Ignatius
• Format: Journal Article
• Language: English
• Published: United States Global Health: Science and Practice 28.04.2022
• Subjects: Anti-HIV Agents - adverse effects; Anti-Retroviral Agents - adverse effects; Commentaries; HIV Infections - drug therapy; Humans
• ISSN: 2169-575X; 2169-575X
• DOI: 10.9745/GHSP-D-21-00595

Systems established for active drug safety monitoring and management of drug-resistant TB should be leveraged to ensure comprehensive surveillance for active toxicity monitoring during scale-up of newer antiretroviral regimens. The introduction of novel medicines and regimens for antiretroviral (ARV) and TB treatment requires comprehensive surveillance systems for adverse events and adverse drug reactions. Many TB programs have introduced and institutionalized active drug safety monitoring and management (aDSM) platforms for drug-resistant TB. Because HIV programs must develop active ARV toxicity monitoring systems to ensure safe global scale-up of newer regimens, such as tenofovir-lamivudine-dolutegravir, we propose building on existing aDSM infrastructure to actively monitor ARV regimens as a synergistic TB/HIV collaborative activity and to narrow active toxicity monitoring gaps.